

# **TABLE 1**

## ICS is the Cornerstone of Treatment

**ALWAYS** 

- Is it Asthma?
- Prescribe by brand
- Check inhaler technique
- Check Compliance

- Ensure patient is using an ICS or ICS in a combination inhaler

• Use a spacer compatible with MDI

- Provide an Asthma Action Plan
- Identify & document trigger factors
  Maintain lowest controlling therapy

Asthma is not controlled if using >2 reliever inhalers per year. REVIEW if >6 requested per year

## **INITIAL & ADDITIONAL THERAPY OPTIONS**



# INITIAL

Symbicort 200/6 Turbohaler (DPI) 1 puff twice daily OR 2 puffs once daily plus reliever (SABA)

INITIAL



Seretide 50 MDI 2 puffs twice a day (spacer recommended) plus reliever (SABA)

Seretide 125 MDI

2 puffs twice daily (spacer recommended) plus reliever (SABA)

#### LOW/MEDIUM DOSE ICS/LABA



Relvar 92/22 Ellipta (DPI) 1 puff once daily plus reliever (SABA) Not licensed for MART

# **LTRA**

CONTINUE with ICS

**ADD** LTRA once daily

If no benefit

#### after 4 weeks then **STOP LTRA**

Leukotrine Receptor Antogonist

12-14 years Montelukast 5mg Chewtab

15+ years Montelukast 10mg tablet once a day at night



plus reliever (ICS/Formoterol) (max 12 puffs/day) **SMART** 

# **ADDITIONAL**

**MEDIUM DOSE ICS/LABA** 

see (TABLE 1) and try different options before stepping up

# **ADDITIONAL**

Symbicort 200/6 TurboHaler (DPI) 2 puffs twice daily plus reliever (SABA)

For patients who are already using Symbicort (above) with separate reliever - SABA; and using 3 or more SABAs per year, consider replacing SABA Reliever with ICS/Formoterol Reliever - (SMART)

# **RELIEVERS**

## **RELIEVER: SABA**



1 puff as required



Salbutamol Easyhaler 100mcgs 2 puffs as Or 200mcgs 1 puff as required



Salamol 100 MDI (Spacer recommended) 2 puffs as required



Salamol 100 Easi-Breathe 2 puffs as required

To be prescribed in addition to daily ICS or daily ICS/LABA

# **RELIEVER: ICS/FORMOTEROL**



To be prescribed in addition to daily low dose ICS/Formoterol (MART)

## **CARBON FOOTPRINT**

- HFC in MDIs contribute to the NHS carbon footprint DPIs have a lower carbon footprint BUT patient preference and inspiratory flow **MUST** be considered before offering DPIs
- UNCONTROLLED ASTHMA CONTRIBUTES TO A HIGHER CARBON FOOTPRINT

**Greener Inhaler Toolkit for GP Practices** https://bit.ly/3xE23Qh



12-17 years

# **REFER to Respiratory**

If you have used above treatment or diagnostic uncertainty

If any concerns refer sooner

## Asthma & Lung UK Inhaler videos

https://www.asthma.org.uk/advice/inhaler-videos





#### **KEY** ICS -Inhaled Corticosteroid LABA - Long Acting Beta<sub>2</sub> Agonist **SABA** - Short Acting Beta<sub>2</sub> Agonist LTRA - Leukotriene Receptor Antagonist MDI -Metered Dose Inhaler Dry Powder Inhaler MART - Maintenance & Reliever Therapy **HFC** - Hydrofluorocarbon

SMART - Single Maintenance & Reliever Therapy

**BDP** - Beclometasone Diproprionate

